I’ve recently had to research this due to working with some highly potent cancer drugs. There is a company called Safebridge Consulting (http://www.safebridge.com/ )that has put out some good info on dealing with potent and ultrpotent compounds.. They even have a Potent Compound Safety Bootcamp. You can find a good article on their system for working with compounds using an Occupational Exposure Banding system in the Journal of Chemical Health and Safety, July/ August 2005.
There was also a very helpful slideshow that I found, but I can only seem to get a partial link. The slideshow is Introduction to Containment of Potent Compounds. Here is a link to the search I found it on http://www.google.com/webhp?nord=1#nord=1&q=Containment+Technology+Forum+2007+INTRODUCTION+TO+CONTAINMENT
It’s the first non-sponsored result.
I hope these help,
Brady P. Arnold
phone (913) 227-7143
fax (913) 227-7199
Here is the clarification regarding my question : ‘’Working with a high potent compound’’
I am working in a pharmaceutical company and what I mean by high potency is very, very active compound (in that case active pharmaceutical ingredient = API) in the human body for the intended pharmacological effect. This generic drug that we will work on in the near future has a daily dosage of only 20 =B5g per day (for that reason I guess it was classified as high potent drug) compare to a low potent drug e.g. 20g per day.
On the other side the LD 50 (mouse) of this compound is 200mg per kg, so it is not very toxic.
Sorry about this misunderstanding and thanks to all of you for the efforts trying to answer my not clear enough question,
Nadejda Spassova, Ph.D
Research Scientist II, R&D
T 514.366.7950ext. 270
9321, Airlie Street, LaSalle, Quebec, Canada H8R 2B2 delmarchem.com
The information transmitted in and attached to this email may contain legally privileged or confidential information that is intended solely for the recipient(s) or entity to which it is addressed. Delivery of this message to anyone other than the intended recipient(s) does not in any way waive this privilege or confidentiality. Any review, retransmission, or other use of this confidential information by persons or entities other than the intended recipient(s) is prohibited. If you have received this email in error, please contact the sender and delete this material from any computer.
L’information contenue dans cet email peut contenir de l’information l=E9galement privil=E9gi=E9e ou confidentielle qui s’adresse uniquement =E0(aux) destinataire(s) ou =E0 l’entit=E9. L’envoi de ce message =E0 quiconque autre que le(s) destinataire(s) n’=E9carte pas toutefois cette privil=E9gie ou cette confidentialit=E9. Toute r=E9vision, retransmission, ou autre utilisation de cette information confidentielle par des personnes ou des entit=E9s autre que le(s) destinataire(s) est interdit. Si vous avez re=E7u ce message par erreur, veuillez contacter l’exp=E9diteur et supprimer le message de votre ordinateur.
This e-mail message, including any attachment, is for the sole use of the intended recipient(s) and may contain legally privileged and/or confidential information. Unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient of this message or if this message has been addressed to you in error, please contact the sender by reply e-mail and delete and destroy all copies of the original message.
Previous post | Top of Page | Next post